ALNY250516P300000
- 56.80
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $287 to $371
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $325
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Reports Strong Start to 2025
Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q1 2025 Earnings Conference
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Research Alert: Alny Q1 Results Point To A Strong Start To The Year; Guidance Maintained
Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises
Alnylam Pharmaceuticals | 10-Q: Q1 2025 Earnings Report
Alnylam Sees FY25 Non-GAAP Operating Income Achieving Profitability >ALNY
Alnylam Sees Regulatory Approval for AMVUTTRA for ATTR-CM in Japan in 2Q and in European Union in 3Q
Alnylam Intends to Initiate TRITON-CM Phase 3 Clinical Trial of Nucresiran in Patients With ATTR-CM in 1H >ALNY
Alnylam Pharmaceuticals | 8-K: Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
Express News | Alnylam Pharmaceuticals Inc - Reiterates 2025 Guidance
Earnings Flash (ALNY) Alnylam Pharmaceuticals Reports Q1 Loss $-0.01 Per Share, Vs. FactSet Est of $-0.38
Express News | Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
Express News | Alnylam Pharmaceuticals Q1 Adjusted Operating Income USD 74.789 Million Vs. IBES Estimate USD -105.3 Million
Express News | Alnylam Pharmaceuticals Q1 Basic EPS USD -0.44